Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

carbidopa

A hydrazine derivative of dopa. Carbidopa is a peripheral dopa decarboxylase inhibitor that is used as an adjunct to levodopa administration to prevent peripheral biosynthesis of levodopa to dopamine, thereby reducing peripheral side effects. Carbidopa does not penetrate the blood brain barrier so that levodopa, after it reaches the brain, can be metabolized to dopamine by dopa decarboxylase where it exerts its effect on dopamine receptors.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	alpha-methyldopahydrazine
US brand name:	Lodosyn
Chemical structure:	(-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-,(S)-

carbidopa

Search NCI's Drug Dictionary